top of page

GLP-1s and MCAS: A Perk Worth Considering?

Writer: Dr. Brenda Tapp Leonard, ND
Dr. Brenda Tapp Leonard, ND
Oct 26
3 min read

You’ve discussed a GLP-1 medication with your healthcare provider. There’s a medical reason to consider it, perhaps type 2 diabetes or weight management, but you haven’t quite decided.


Will the benefits outweigh the side effects? How will your body respond? Is this something you want to commit to?


If you also have mast cell activation syndrome (MCAS), there’s another piece of information worth bringing into that decision: early research suggests these medications might offer an additional benefit for some MCAS-related symptoms.


As a naturopathic doctor in Peterborough, I’m interested in research that helps us consider a patient’s health concerns together. This finding may be relevant when someone is already considering a prescription.


Considering GLP-1 medications when you have MCAS

The first question remains: Is this medication a good choice for the condition we’re prescribing it for?


That decision should consider your health history, the specific medication, its established benefits, potential side effects, cost, and your preferences.


Then we can ask a second question: Could there be an additional benefit for symptoms you’re already living with?


For someone with MCAS, that is an interesting question. The answer is still uncertain, but there is published clinical evidence to explore.


What does the research on GLP-1 medications and MCAS show?

A 2025 case series looked at 47 patients with MCAS whose symptoms had been difficult to manage. They received various GLP-1 receptor agonists, and the researchers reported that 89% experienced clinical benefit across a range of MCAS-related problems. The authors called for randomized controlled trials to establish effectiveness and appropriate dosing.


That is a finding worth following. It also needs context.


Researchers reviewed treatment experiences without a control group. Patients received different regimens, and other factors could have contributed to their improvement. This type of study helps identify a promising possibility; it cannot establish that the medication caused the benefit.


An 89% improvement rate in this selected group does not mean you have an 89% chance of feeling better. It also does not tell us which medication would be best, how durable the benefit might be, or who is most likely to respond.


Could GLP-1 medications affect inflammation?

Scientists are investigating how GLP-1 signalling influences inflammation alongside its metabolic effects.


In animal research, activating GLP-1 receptors has reduced signals involved in allergic airway inflammation, including a molecule called IL-33. That gives researchers a biological reason to investigate potential immune effects.


We still need direct evidence showing whether these medications reliably reduce mast cell activation or mediator release in people with MCAS. Broader anti-inflammatory effects do not automatically establish that a drug acts as a mast cell stabilizer.


For now, there is a plausible explanation and an early clinical observation. There is more work to do.


GLP-1 side effects: why your digestive health matters

If you live with MCAS, the possibility of feeling better can be compelling. Your existing symptoms also matter when assessing tolerability.


Semaglutide can cause nausea, vomiting, diarrhea, constipation, and delayed stomach emptying. These effects may overlap with digestive symptoms you already experience, making it harder to tell what is improving and what is a medication side effect. The Canadian Ozempic monograph advises against its use in severe gastroparesis.


Serious allergic reactions have also been reported with semaglutide, so your reaction history needs to be part of the assessment.


A possible additional benefit deserves consideration alongside these practical concerns.


What should you ask your healthcare provider?

If you already qualify for treatment and have diagnosed MCAS, you could bring this question to your prescriber:


“We’re considering this medication for my diabetes or weight management. Given my MCAS, could this emerging research be relevant to my decision, and what would we monitor if I started?”


That opens a useful discussion about expectations, tolerability, and tracking changes in your symptoms.


If you suspect MCAS but have not been assessed, bring that up as well. Symptoms alone do not confirm mast cell activation syndrome, and an improvement after starting a GLP-1 medication would not establish the diagnosis.


The reason to prescribe should stand on its own. Any improvement in MCAS symptoms would be a possible additional benefit, not something to count on.


GLP-1 medications remain unproven as an MCAS treatment, and this research does not justify replacing your existing care. But if you’re already weighing an otherwise appropriate prescription, it is reasonable to put this emerging evidence on the table.


Discussing MCAS in Peterborough

If you’re looking for a Peterborough Naturopath to help you make sense of complex symptoms or emerging research, our approach at Peterborough Centre of Naturopathic Medicine is evidence-informed and individualized.


We can help you review your health concerns, identify questions for your prescribing provider, and consider how different parts of your care fit together.


Book a consultation to discuss your symptoms and health goals. You deserve a treatment conversation that considers the whole picture and is honest about where the evidence ends.


  • Dr Brenda ND



Comments


Contact

  • Instagram
  • Facebook

386 Burnham Street
Peterborough, Ontario
K9H 1T6

Phone: 705-761-6596

Fax: 705-201-5234

health@pcnm.ca

​

Free parking available

behind the building

Working Hours

MONDAY TO FRIDAY : 9AM - 5PM

Appointments available outside these hours, depending on practitioner availability.

Order supplements from our online store

Subscribe to our mailing list

© 2023 Peterborough Centre of Naturopathic Medicine

design by brandbetter

bottom of page